1 reports of this reaction
3.3% of all CHELIDONIUM MAJUS reports
#10 most reported adverse reaction
HEPATOCELLULAR INJURY is the #10 most commonly reported adverse reaction for CHELIDONIUM MAJUS, manufactured by BM Private Limited. There are 1 FDA adverse event reports linking CHELIDONIUM MAJUS to HEPATOCELLULAR INJURY. This represents approximately 3.3% of all 30 adverse event reports for this drug.
Patients taking CHELIDONIUM MAJUS who experience hepatocellular injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOCELLULAR INJURY is moderately reported among CHELIDONIUM MAJUS users, representing a notable but not dominant share of adverse events.
In addition to hepatocellular injury, the following adverse reactions have been reported for CHELIDONIUM MAJUS:
HEPATOCELLULAR INJURY has been reported as an adverse event in 1 FDA reports for CHELIDONIUM MAJUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOCELLULAR INJURY accounts for approximately 3.3% of all adverse event reports for CHELIDONIUM MAJUS, making it a notable side effect.
If you experience hepatocellular injury while taking CHELIDONIUM MAJUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.